DHT, or dihydrotestosterone, does affect women’s hair, and it can drive the same kind of progressive thinning seen in men. But the relationship is more complicated in women. Female scalp follicles carry lower levels of the enzyme that produces DHT and higher levels of a protective enzyme that diverts testosterone toward estrogen instead. The result is that DHT still plays a role in female hair loss, but the clinical pattern, the triggers, and the treatment landscape all look different.
How DHT Causes Hair to Thin
In both women and men, DHT is converted from testosterone inside the hair follicle by an enzyme called 5-alpha reductase. When DHT binds to receptors on a susceptible follicle, it gradually shrinks that follicle from a thick, pigmented terminal hair into a fine, nearly invisible vellus hair. This process is called miniaturization, and it is the hallmark of androgenetic alopecia regardless of sex.1PubMed. Androgenetic alopecia in women The key phrase there is “susceptible follicle.” Not every hair follicle responds to DHT the same way, which is why hair loss follows recognizable patterns on the scalp rather than occurring uniformly.
Why the Pattern Looks Different in Women
Men with androgenetic alopecia tend to lose hair at the temples and crown in a distinct receding pattern. Women usually experience diffuse thinning across the top of the scalp while keeping their frontal hairline largely intact. This difference traces back to enzyme levels inside the follicles themselves. Women’s frontal follicles have roughly three times less 5-alpha reductase type I, and about three and a half times less type II, compared to men’s frontal follicles.2PubMed. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia Less of that enzyme means less local DHT production, which translates to less aggressive miniaturization at the front of the scalp.
Women’s follicles also produce considerably more aromatase, a separate enzyme that converts testosterone into estradiol rather than DHT.3PubMed. 17alpha-estradiol induces aromatase activity in intact human anagen hair follicles ex vivo Think of aromatase as a competing pathway: the more testosterone gets shunted toward estradiol, the less is available for conversion to DHT. This built-in protection helps explain why women rarely go fully bald the way men can, even when the same underlying process is at work. It also explains why disruptions to estrogen levels can tip the balance.
Normal Bloodwork Does Not Rule Out DHT-Driven Thinning
One of the most frustrating aspects of female hair loss is that many women with clear signs of androgenetic alopecia have perfectly normal androgen levels in their blood. This often leads to the mistaken conclusion that hormones are not involved. In reality, the DHT concentration that matters most is produced locally, inside the follicle itself. Testosterone circulating in the blood gets converted to DHT right at the follicle by 5-alpha reductase, so a woman can have unremarkable serum testosterone and still have elevated DHT activity at the level of her scalp.4PubMed. 5α-Reductase isozymes and aromatase mRNA levels in plucked hair from young women with female pattern hair loss
What seems to matter more than how much androgen is floating around in the bloodstream is how sensitive a given follicle is to DHT and how actively the enzymes inside it are producing or neutralizing the hormone. Research points to the genetically determined sensitivity of follicles to DHT and their individual reactions to androgen concentration as the most important factors.5PubMed Central. Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia This is why two women with identical hormone panels can have very different hair outcomes.
Menopause Shifts the Balance
If aromatase and estrogen act as a buffer against DHT, then losing estrogen upsets that balance in a predictable way. During menopause, ovarian estrogen production drops sharply while androgen levels decline more slowly. The result is a relative increase in androgens, even though androgen levels are not actually rising. This hormonal shift directly impacts the hair follicle, which is an estrogen-sensitive tissue. Women commonly notice decreased hair density, finer-caliber hairs, and changes in texture after menopause.6PubMed. Menopause and hair loss in women: Exploring the hormonal transition
Beyond just the androgen-to-estrogen ratio, the loss of estrogen may also compromise the metabolic and vascular support that keeps hair follicles healthy. Female pattern hair loss, telogen effluvium (a stress-related shedding condition), and frontal fibrosing alopecia all occur more frequently in postmenopausal women.7PubMed. Skin, hair and beyond: the impact of menopause Hair changes at menopause can also include increased facial hair growth, an ironic counterpart to scalp thinning. The same androgens that shrink scalp follicles can stimulate facial ones, since follicles in different body regions respond to DHT in opposite ways.
Understanding this hormonal tipping point matters because it means that many women will not notice hair loss until their 40s or 50s, even if the genetic susceptibility was always there. The protective buffer of estrogen simply held it at bay for decades.
PCOS and Elevated Androgens
Polycystic ovary syndrome is one of the clearest examples of systemic hyperandrogenism driving hair loss in younger women. Women with PCOS often produce excess androgens, which raises DHT activity both in the bloodstream and at the follicle. Research describes the relationship as bidirectional: local follicle pathology both amplifies and is amplified by systemic hyperandrogenism, making androgen action a necessary but insufficient piece of the puzzle on its own.8PubMed Central. Androgenetic alopecia in polycystic ovary syndrome: a cutaneous marker of systemic metabo-inflammatory and endocrine dysfunction
Interestingly, not every woman with PCOS develops hair loss. Among those who do, factors beyond androgens alone appear to contribute. Body mass index, triglyceride levels, and specific genetic variations have all been found to independently predict female pattern hair loss in women with PCOS, suggesting the condition creates a metabolic and hormonal environment that amplifies what DHT is doing at the follicle.9PubMed. HSD3B1 gene polymorphism and female pattern hair loss in women with polycystic ovary syndrome
Genetic Susceptibility Is Not the Same as in Men
It would be convenient if the genetics of female and male pattern hair loss were identical, just expressed at different severities. But the evidence says otherwise. Research in a Chinese Han population found that the androgen receptor gene loci most strongly linked to male androgenetic alopecia did not serve as reliable genetic markers for female pattern hair loss.10PubMed Central. Evaluation of Susceptibility Genes/Loci Associated with Male Androgenetic Alopecia for Female-Pattern Hair Loss in a Chinese Han Population and a Brief Literature Review This supports the broader idea that the pathogenesis of female pattern hair loss is not simply a milder version of the male condition. There are overlapping mechanisms, especially the role of DHT, but distinct genetic risk factors and potentially additional non-androgenic pathways contribute to women’s hair loss.
This has practical implications for how clinicians evaluate female patients. A family history of male baldness on either side of the family does increase a woman’s risk, but the genetic architecture is not a one-to-one copy. Some women with no family history of male baldness still develop significant hair thinning, and vice versa.
Telling DHT-Driven Thinning Apart From Other Types of Hair Loss
Not all hair loss in women is caused by DHT. Telogen effluvium, a condition triggered by stress, illness, nutritional deficiencies, or hormonal changes like childbirth, causes diffuse shedding that can look very similar to female pattern hair loss at first glance. The distinction matters because the treatment strategies are entirely different. Telogen effluvium usually resolves on its own once the trigger is removed, while DHT-driven thinning is progressive and requires ongoing management.
Dermatologists use several tools to differentiate between the two. One hallmark of androgenetic alopecia is miniaturization: under magnification, the affected area shows a wide variation in hair shaft diameter, with more than a 20 percent difference between the thickest and thinnest hairs. Diagnostic criteria for female androgenetic alopecia include increased yellow dots in the frontal scalp, decreased average shaft thickness compared to the back of the head, and a higher proportion of very thin hairs at the front.11Anais Brasileiros de Dermatologia. Clinical and histological challenge in the differential diagnosis of diffuse alopecia: female androgenetic alopecia, telogen effluvium and alopecia areata – part I On biopsy, the ratio of terminal to vellus hairs can help clinch the diagnosis. A simple wash test can also be informative: women with telogen effluvium shed many more hairs during a standardized wash (averaging around 438 in one study), with most of them being full-length. Women with female pattern hair loss shed fewer hairs overall but a higher proportion are short.12PubMed. Non-invasive method distinguishes chronic telogen effluvium from mild female pattern hair loss: clinicopathological correlation
The Role of Inflammation Beyond DHT
DHT is not working in isolation. Research has identified a layer of chronic low-grade inflammation around miniaturizing follicles that appears to contribute to the hair loss process. Prostaglandin D2, a molecule that inhibits hair growth and promotes follicle miniaturization, has been found at elevated levels in balding scalps, though so far this has only been confirmed in men. Interestingly, anti-inflammatory treatments do not seem to improve female pattern hair loss, and the exact links between inflammation and other causal factors remain unclear.13JAAD Reviews. An updated landscape of female pattern hair loss – Section: Microinflammation This is one of the areas where the science gets thin. It is possible that inflammation is a downstream consequence of DHT-driven damage rather than a separate driver, but researchers have not fully sorted this out yet.
The scalp microbiome may also play a role. In androgenetic alopecia, there appears to be a coupling between androgen activity, changes in scalp lipids (sebum), and shifts in the microbial community on the scalp, creating a kind of inflammatory feedback loop that may worsen the condition beyond what DHT alone would do.14PubMed Central. The Scalp Microbiome-Hair Axis: Mechanisms and Therapeutic Translation
Treatments That Block DHT in Women
If DHT is driving hair loss, one logical approach is to block it. In men, the go-to prescription is finasteride, which inhibits 5-alpha reductase and reduces DHT production. In women, the same drug is used but with important caveats. Finasteride at doses ranging from 1 to 5 milligrams daily has shown increased hair density and reduced shedding in case reports and series involving both premenopausal and postmenopausal women.15PubMed Central. Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date – Section: Therapeutic Efficacy of Finasteride in Female Pattern Hair Loss One study of 137 women found that finasteride at 2.5 milligrams per day was clinically effective in about 62 percent of cases, with premenopausal women and those with less advanced hair loss responding best.16Pakistan Journal of Medical and Health Sciences. Clinical Efficacy of Oral Administration of Finasteride at a dose of 2.5mg/Day in Women with Female Pattern Hair Loss
Dutasteride, which blocks both types of 5-alpha reductase rather than just one, has also shown promise. In a three-year study comparing finasteride and dutasteride in 120 women, about 82 percent in the finasteride group and 83 percent in the dutasteride group showed increased hair thickness. In women under 50, dutasteride performed better than finasteride specifically at the central and vertex areas of the scalp.17PubMed. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia A scoping review reported that low-dose dutasteride improved hair loss in as many as 80 percent of female patients over three years.18JAAD Reviews. The efficacy of oral finasteride and dutasteride in the treatment of female pattern hair loss and frontal fibrosing alopecia in women: A scoping review Still, a systematic review noted that high-quality research specifically studying these drugs in female populations remains limited, and much of the evidence comes from case reports and small series rather than large randomized trials.19PubMed Central. Comparison between dutasteride and finasteride in hair regrowth and reversal of miniaturization in male and female androgenetic alopecia: a systematic review
Spironolactone takes a different approach. Rather than reducing DHT production, it blocks DHT from binding to androgen receptors on the follicle, reducing the downstream effects of sebum overproduction and miniaturization.20PubMed Central. The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis Spironolactone is widely prescribed for female pattern hair loss in clinical practice, partly because it has a longer safety track record in women than finasteride does, though it carries its own side effects like potassium elevation and menstrual irregularities.
The Pregnancy Safety Problem
Any drug that interferes with androgen activity poses a risk to a developing male fetus. Finasteride and dutasteride can potentially cause birth defects, particularly hypospadias, a condition where the urethral opening is misplaced.21PubMed. Finasteride use during pregnancy and early neonatal outcome: a case report This makes prescribing these medications to women of childbearing age a careful calculation. Most clinical practices require reliable contraception throughout treatment and often ask patients to sign written acknowledgment of the risks.22Journal of Dermatology and Dermatologic Surgery. Pregnancy and Neonatal Outcome with Maternal Exposure to Finasteride: Case Series Spironolactone carries a similar antiandrogen warning, and both finasteride and spironolactone are typically discontinued well before any planned pregnancy. For postmenopausal women who are beyond childbearing, these concerns do not apply, which partly explains why the evidence base is stronger in that group.
Saw Palmetto as a Milder DHT Blocker
For women who are uneasy about prescription antiandrogens, saw palmetto is the most studied botanical alternative. It is thought to work through a similar mechanism to finasteride, inhibiting 5-alpha reductase, though at a much weaker level. Across several randomized trials and cohort studies, supplements containing saw palmetto in doses of 100 to 320 milligrams showed positive effects including improved hair counts and stabilized progression in patients with androgenetic alopecia.23PubMed Central. Natural Hair Supplement: Friend or Foe? Saw Palmetto, a Systematic Review in Alopecia A 16-week placebo-controlled trial with 80 male and female subjects found that a standardized saw palmetto oil reduced hair fall by up to 29 percent when taken orally and about 22 percent when applied topically, with increases in hair density in both groups.24PubMed Central. Oral and Topical Administration of a Standardized Saw Palmetto Oil Reduces Hair Fall and Improves the Hair Growth in Androgenetic Alopecia Subjects – A 16-Week Randomized, Placebo-Controlled Study
The caveats here are real: the quality of evidence is modest, many studies use combination supplements rather than isolated saw palmetto, and the effect size is likely smaller than what prescription drugs offer. But for women with mild thinning or those looking for a lower-risk starting point, it is a reasonable option to discuss with a dermatologist. A more recent trial also reported that a proprietary saw palmetto extract safely promoted hair growth in both men and women with self-perceived thinning hair over a 90-day period.25PubMed Central. The Safety and Efficacy of a Proprietary Bioactive Fatty Acids Extract From Saw Palmetto (Serenoa repens) for Promoting Hair Growth and Reducing Hair Loss in Adults With Self-Perceived Thinning Hair: 90-Day Results
The Emotional Toll Is Greater for Women
Socially, hair loss is normalized for men in a way it simply is not for women. Research comparing the psychological effects of androgenetic alopecia between sexes found that while hair loss was stressful for both, it was substantially more distressing for women. Women with androgenetic alopecia had a more negative body image and showed a pattern of less adaptive functioning compared to female controls.26Journal of the American Academy of Dermatology. Psychological effects of androgenetic alopecia on women: Comparisons with balding men and with female control subjects This is worth naming because it affects how women engage with treatment. The distress often drives women to seek help earlier, but it can also make them vulnerable to unproven products marketed with dramatic before-and-after photos. The emotional weight is real and should factor into how clinicians approach the conversation, particularly when the treatment options are off-label, take months to show results, and come with the caveat that they slow or stop progression rather than restore what has already been lost.